HIGGINS ARTHUR J 4

What Happened
Arthur J. Higgins, a non-employee director of Zimmer Biomet Holdings, received awards on May 22, 2026 consisting of 875.35 phantom stock units and 1,517.274 restricted stock units (total 2,392.624 units). Both grants were recorded at $0.00 (no cash paid). These are derivative awards that convert 1-for-1 into company common shares under the plan terms.

Key Details

• Transaction date: 2026-05-22; Report filed: 2026-05-27 (filed within the SEC’s 2-business-day window, accounting for the Memorial Day holiday).
• Grant details: 875.35 phantom stock units (Deferred Compensation Plan for Non-Employee Directors) and 1,517.274 RSUs; both recorded at $0.00.
• Conversion/settlement: Conversion/exercise price is 1-for-1. Phantom units and RSUs will be settled in shares; phantom units are to be settled within 60 days after the director’s service ends.
• Vesting/deferral: The RSUs are immediately 100% vested but are subject to mandatory deferral until the later of (1) the director’s termination of service or (2) three years after the grant date. Some RSUs from prior years may have different deferral schedules.
• Dividends: The phantom units include 106.777 units accrued on April 30, 2026 under a dividend reinvestment provision.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Filed May 27, 2026; appears timely (within required business-day window).

Context
These awards are compensation grants under the company’s director deferred compensation plan and RSU program. They do not represent an open-market purchase (a bullish signal) nor a sale (a liquidity event); rather, they are deferred compensation that will convert to shares under plan terms and upon cessation of service. For retail investors, such grants are routine director compensation and should be interpreted as compensation-related, not necessarily a direct signal of the director’s short-term view on the stock.